|Mr. Jean-Christophe Tellier||Chief Exec. Officer and Exec. Director||3.77M||N/A||59|
|Mr. Detlef Thielgen||Chief Financial Officer and Exec. VP||N/A||N/A||58|
|Ms. Anna S. Richo||Exec. VP and Gen. Counsel||N/A||N/A||58|
|Dr. Bharat Tewarie||Chief Marketing Officer and Exec. VP||N/A||N/A||57|
|Prof. Iris L??w-Friedrich||Chief Medical Officer, Head of Devel. & Medical Patient Value Practices and Exec. VP||N/A||N/A||58|
UCB SA, a biopharmaceutical company, focuses on the discovery and development of medicines and solutions for people living with severe diseases of the immune system or of the central nervous system. Its core products include Cimzia for ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, psoriatic arthritis, and rheumatoid arthritis; Keppra, Vimpat, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. The company also offers Zyrtec and Xyzal for allergy; Venlafaxine ER for depressive and anxiety disorders; Nootropil for cognitive disorders; and Xyrem for narcolepsy. Its product pipeline includes UCB0942 for highly drug resistant epilepsy; dapirolizumab pegol for systemic lupus erythematosus; bimekizumab for various indications; bimekizumab, add-on to Cimzia for rheumatoid arthritis; seletalisib for Sj??gren's syndrome; UCB7665 for immune thrombocytopenia; UCB1332 for Parkinson's disease; UCB4144/VR942 for asthma; UCB6673 for immunological diseases; UCB3491 for epilepsy; and UCB7858 for auto-inflammatory diseases. UCB SA was founded in 1928 and is headquartered in Brussels, Belgium.
UCB SA’s ISS Governance QualityScore as of January 1, 2018 is 5. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 7; Compensation: 5.